Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
This randomized phase II trial compares enzalutamide with standard androgen deprivation
therapy in reducing incidence of metabolic syndrome in patients with prostate cancer that has
spread to other places in the body. Metabolic syndrome is defined as changes in cholesterol,
blood pressure, circulating sugar levels, and body weight. Previous studies have shown that
patients with prostate cancer, who have been treated with standard medical therapy that
lowers testosterone levels, have an increased risk of these changes. Hormone therapy using
enzalutamide may fight prostate cancer by blocking the use of testosterone by the tumor cells
instead of lowering testosterone levels. It is not yet known whether prostate cancer patients
who receive enzalutamide will have reduced incidence of metabolic syndrome than patients who
receive standard androgen deprivation therapy.